WebExplore Ongoing Studies. Ladiratuzumab vedotin targets LIV-1 using our proprietary antibody–drug conjugate (ADC) technology. LIV-1 is expressed in most metastatic breast …
Strong Efficacy and Safety Data Observed With …
WebThis study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). WebHrom. Hrom. Receptor Insulinolikog faktora rasta 1 ( IGF-1) jest protein ćelijske površine koji je kod ljudi kodiran genom IGF-1 sa hromosoma 15. To je transmembranski receptor koji se aktivira hormonom koji se zove insulinoliki faktor rasta 1 ( IGF-1) i srodnim hormonom zvanim IGF-2. Pripada velikoj klasi tirozin-kinaznih receptora. part ex cars wakefield
AbbVie Announces U.S. FDA Granted Breakthrough Therapy ... - BioSpace
WebMay 26, 2024 · Telisotuzumab vedotin (ABBV-399; teliso-v [T]), an anti–c-Met Ab and monomethyl auristatin E drug conjugate, showed efficacy as monotherapy (mono) and combined with erlotinib (T+Er) in a phase 1/1b trial (NCT02099058) in NSCLC patients (pts) with c-Met OE. Here, c-Met OE (by immunohistochemistry [IHC]) and its association with … WebMar 28, 2014 · Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin. Drug: Telisotuzumab vedotin It is administered by infusion in 21-day dosing cycles. WebA Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Latest version (submitted April 10, 2024) on ClinicalTrials.gov. A study version is represented by a row in the table. partex beverage report